How Far Do the Complaints of Patients with Parkinson’s Disease Reflect Motor Fluctuation? Quantitative Analysis Using a Portable Gait Rhythmogram

Table 1

Clinical features of patients with Parkinson’s disease.

Case no.	Age (years)	Gender	Duration (years)	M H-Y	UPDRS Part III				Medication
					Total score	Gait	Postural stability	Bradykinesia
Subjective good
1	73	M	3.6	3	12	1	2	2	L-dopa 300 mg, Ama 200 mg
2	73	M	3.6	3	12	1	2	2	L-dopa 300 mg, Ama 200 mg
3	79	M	1.3	3	44	2	2	2	L-dopa 300 mg
4	70	F	2.8	3	11	1	2	1	L-dopa 300 mg, Pra 1.5 mg
5	55	M	2.5	2	11	0	0	0	Rop 4 mg, Ama 200 mg
6	70	F	3.6	2.5	9	1	1	1	L-dopa 300 mg
7	75	M	3.0	3	23	1	2	2	None
8	64	F	2.6	3	16	2	1	1	Rop 2 mg, Ama 200 mg
9	73	F	7.7	1.5	10	0	0	0	L-dopa 300 mg, Pra 3 mg, Ama 100 mg
10	83	M	3.7	2	12	2	0	1	Ama 100 mg
11	63	F	0.5	2	23	1	0	1	None
12	76	M	3.1	2	16	0	0	0	L-dopa 300 mg
13	79	M	3.5	3	34	1	2	2	L-dopa 300 mg
14	79	M	3.5	2.5	29	1	1	2	L-dopa 200 mg, Tri 4 mg
15	78	M	8.3	2	11	0	0	0	None
16	79	M	3.8	3	23	1	2	1	L-dopa 300 mg, Pra 1.5 mg
17	78	M	2.9	2.5	14	1	1	1	L-dopa 300 mg
18	75	F	2.4	3	35	2	2	2	L-dopa 300 mg, Pra 1.0 mg
19	77	M	17.6	3	30	2	1	3	Pra 2.0 mg, Ama 100 mg
20	75	M	11.7	3	26	1	2	2	L-dopa 300 mg
21	64	M	1.8	1.5	10	0	1	1	L-dopa 300 mg, Pra 1.5 mg
22	63	F	1.3	2	21	0	0	1	None
23	63	F	1.4	2	19	0	0	1	Pra 2 mg
Subjective not good
24	76	M	17.3	3	36	2	2	3	Ama 100 mg
25	67	M	3.3	2	30	1	1	1	L-dopa 300 mg, Ama 200 mg
26	71	M	3.4	3	29	1	1	1	L-dopa 300 mg, Rop 4 mg
27	69	M	1.0	3	17	1	2	2	None
28	59	M	9.0	2	15	0	0	1	L-dopa 300 mg, Pra 3 mg, Sel 5 mg, Ama 200 mg
29	77	M	2.8	2.5	21	1	1	1	L-dopa 400 mg
30	82	M	3.9	4	31	2	1	2	L-dopa 300 mg, Rop 3 mg
31	64	M	1.5	1.5	8	0	0	1	L-dopa 300 mg
32	79	M	7.7	3	21	2	1	1	L-dopa 400 mg, Per 1.25 mg, Sel 5 mg
33	78	F	2.0	3	31	1	2	3	None
34	81	F	8.2	3	17	1	2	2	L-dopa 300 mg, Rop 2 mg
35	65	F	3.3	2.5	19	1	2	2	Pra 1 mg, Ama 200 mg
36	77	F	9.6	2.5	23	1	1	1	L-dopa 300 mg, Rop 2 mg
37	56	F	2.3	3	18	1	2	2	L-dopa 300 mg, Rop 9 mg, Ama 200 mg
38	73	F	0.5	3	11	0	2	1	None
39	74	F	2.3	3	35	2	2	2	L-dopa 300 mg
40	70	F	2.8	3	14	1	2	1	L-dopa 300 mg
41	66	F	2.7	2.5	15	1	1	1	L-dopa 200 mg, Rop 6 mg
42	72	M	8.3	3	24	1	1	1	L-dopa 400 mg, Rop 5 mg
43	65	M	1.7	1.5	10	1	0	0	Tri 4 mg
44	64	F	12.8	3.5	21	1	2	1	L-dopa 500 mg, Pra 4 mg, Ent 500 mg

M H-Y: modified Hoehn and Yahr stage, UPDRS: unified Parkinson's disease rating scale, gait: “gait” score, postural stability: “postural stability” score, bradykinesia: “body bradykinesia and hypokinesia” score, Ama: amantadine, Pra: pramipexole, Rop: ropinirole, Tri: trihexyphenidyl, Sel: selegiline, Ent: entacapone, subjective good: patients who did not notice wearing off, and subjective wearing off: patients who noticed subjectively wearing off.